Caravelle Intl Gr (NASDAQ:CACO) Stock, Quote.Headers.trade-ideas

Caravelle International

Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company primarily derives freight revenue from voyage contracts and provides vessel service.

wall street subway shutter

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHL

AEMD

APDN

BNED

CACO

CYCC

GRPN

IONM

KITT

KOSS

NVAX

PRTG

TVGN

WAVD

Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

AGIL

AIXI

AXLA

BGLC

BNOX

EBET

FLAG

GSAT

GSHD

HKIT

ICCT

INBX

IONR

JOAN

LFVN

LXEH

NBSE

NCNC

NFTG

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PLSE

RETO

SECO

SISI

TIGR

TIVC

TSHA

TTOO

VRRM

Gainers


	Axcella Health Inc.  (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.


Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

BEDU

BTCM

DRTS

NPCE

ORGS

TCBP

VHNA

Gainers


	Tivic Health Systems, Inc.  (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on AmerisourceBergen’s third-party marketplace.


Why Alpha Tau Medical Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Caravelle International Group - Ordinary Shares

Caravelle International Group

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,049.30 today based on a price of $56.95 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $4,546.33 today based on a price of $122.16 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Citigroup analyst Atif Malik maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Puma Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Puma Biotechnology</h2>
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -17.07%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -9.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.17, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PBYI

Where Puma Biotechnology Stands With Analysts

During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.
<img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>Delving into Lennox Intl's Background</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Unraveling the Financial Story of Lennox Intl</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of 2.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 51.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Lennox Intl

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,815.64 today based on a price of $161.40 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. 
Buying $100 In CNQ: If an investor had bought $100 of CNQ stock 5 years ago, it would be worth $279.38 today based on a price of $34.42 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 19.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 3.6, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

Canaccord Genuity analyst Dalton Baretto maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.

TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

Canaccord Genuity analyst Mike Mueller maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.

TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.

Earnings

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

PayPal Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has 20.55 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

Owens-Corning's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Owens-Corning's Recent Short Interest

Kohl's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 40.73 million shares sold short, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(KSS) - Analyzing Kohl's's Short Interest

<a href="https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393">https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393</a>
Howard Schultz, the former Starbucks chief executive, is opposing a potential settlement between the company and activist investor Elliott Investment Management, in the latest sign of tension at the world's largest coffee chain. The quasi-founder of Starbucks has made his opposition to an Elliott settlement known to some board members, said people familiar with the matter. Schultz had criticised its leadership publicly in recent months despite no longer having a formal role at the company. He remains Starbucks's sixth-largest shareholder, with a holding of about $1.6bn. Elliott, known for being an aggressive investor, has built a sizeable minority stake in the $86bn company and has privately pushed for change in recent weeks, including board representation, in an attempt to revive Starbucks' lacklustre performance. Schultz and Elliott have not been in contact over this matter, one person said. Companies under pressure from activists such as Elliott often seek to negotiate agreements with them rather than face a public fight, but the status of any settlement discussions between Starbucks and Elliott remain unclear. "Howard left the board a year ago and in his limited contact with the board since, his input has always focused on the values and culture of Starbucks as the primary driver of success and performance," a person close to Schultz said. The billionaire former coffee machine salesman led the company three separate times — for about 14 years starting in 1986, then again from 2008 to 2017, and most recently as interim CEO from 2022 to 2023.&nbsp; He was succeeded as CEO last year by Laxman Narasimhan, who joined from UK-based consumer health and hygiene group Reckitt. Schultz remains chair emeritus but left the company's board and has said he does not have access to financial information.
 Schultz, who has said he has no interest in returning as CEO, has remained vocal on the sidelines. This spring he criticised the company's performance on LinkedIn, penning an open letter that said senior leaders and board members needed "to spend more time with those who wear the green apron". He also made an appearance on business podcast Acquired in June, speaking about the history of Starbucks and his recommendations for management. "It hasn't been a great year for Starbucks," he said. "In fairness to Laxman, there's a lot of external issues that have contributed to the pressure, like on every company. But the company has not executed the way that I think it should have." "If the company is doing a drift towards mediocrity, I hold leadership, and the board responsible for that," he said later in the three-hour podcast. Starbucks's share price has fallen about 20 per cent since the start of 2024. The company cut its financial guidance in January and again in April, when it reported a 4 per cent decline in quarterly comparable store sales that was the first such drop since late 2020. It is due to announce results for its fiscal third quarter on Tuesday. Starbucks has made changes to its board over the past year. Three new members, including the CEOs of YouTube and T-Mobile, Neal Mohan and Mike Sievert, joined earlier this year. This spring, Microsoft CEO Satya Nadella left the board. Spokespeople for Schultz, Starbucks and Elliott declined to comment.

Legal

Management

SBUX

'Howard Schultz Opposes Starbucks Settlement With Activist Investor Elliott' - Financial Times

Offerings

ALRN

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

Paragon Technologies, Inc. ("Paragon"), a diversified holding company and a large shareholder of Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>), ("Company" or "OPT"), issues the following statement to OPT shareholders:
On July 5, OPT filed a proxy statement calling for a special meeting of shareholders on August 30, 2024, asking shareholders to approve increasing the Company's authorized shares to 200 million, up from 100 million.
On July 25, 2025, OPT announced Fiscal 2024 financial results revealing that it lost $27.4 million in fiscal 2024 versus $26.3 million in fiscal 2023.

OPTT

PGNT

Paragon Technologies Recommends Ocean Power Shareholders Vote AGAINST Its Plan To Increase Its Authorized Shares By 100M

Caravelle International reports 1H results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday morning!



Moving stocks are an acquisition offer, earnings reports, clinical trial data and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Critical Metals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crml-stock-quote/">CRML</a>) stock is rocketing 200% higher without any clear news.</li>



<li>BitFuFu (NASDAQ:<a href="https://investorplace.com/stock-quotes/fufu-stock-quote/">FUFU</a>) shares are soaring more than 155% with heavy pre-market trading.</li>



<li>Ainos (NASDAQ:<a href="https://investorplace.com/stock-quotes/aimd-stock-quote/">AIMD</a>) stock is surging over 91% with strong early morning trading.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) shares are gaining more than 46% after getting <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318127542&amp;type=PDF&amp;symbol=RNLX&amp;cdn=96ac912de69094ad9090bec33299c8fc&amp;companyName=Renalytix+plc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-04">an unsolicited acquisition offer</a>.</li>



<li>Akero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/akro-stock-quote/">AKRO</a>) stock is increasing over 43% alongside <a href="https://www.nasdaq.com/press-release/akero-therapeutics-reports-statistically-significant-histological-improvements-at">positive Phase 2b clinical trial results</a>.</li>



<li>Energem (NASDAQ:<a href="https://investorplace.com/stock-quotes/encp-stock-quote/">ENCP</a>) shares are rising 40% following its <a href="https://www.nasdaq.com/press-release/energem-corp.-announces-shareholder-approval-of-business-combination-with-graphjet">recent public debut</a>.</li>



<li>Jaguar Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/jagx-stock-quote/">JAGX</a>) stock is climbing more than 26% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318126678&amp;type=PDF&amp;symbol=JAGX&amp;cdn=b757f53f4f9ff8519cfa92b851d5620f&amp;companyName=Jaguar+Health+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-01">debt exchange agreement</a>.</li>



<li>89bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/etnb-stock-quote/">ETNB</a>) shares are jumping over 26% despite a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318126329&amp;type=PDF&amp;symbol=ETNB&amp;cdn=c0de848983eb8c9643e4945463b23ee0&amp;companyName=89bio+Inc.&amp;formType=NT+10-K&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-K+405%2C+10-K%2C+10-KSB+405%2C+10-KSB%2C+10-KT%2C+or+10-KT405&amp;dateFiled=2024-03-01">late annual filing</a>.</li>



<li>Phunware (NASDAQ:<a href="https://investorplace.com/stock-quotes/phun-stock-quote/">PHUN</a>) stock is getting a more than 22% boost as the Supreme Court is expected to weigh on Donald Trump&rsquo;s <a href="https://www.nbcnews.com/politics/supreme-court/supreme-court-release-decisions-monday-trump-colorado-ruling-strong-po-rcna141567">eligibility to run for President</a>.</li>



<li>Imunon (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnn-stock-quote/">IMNN</a>) shares are up over 21% on Monday morning.</li>
</ol><h2>Top 10 Losers</h2>



<ol><li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) stock is plummeting close to 45% with a <a href="https://finance.yahoo.com/news/biovie-inc-announces-proposed-public-215800520.html">proposed public offering</a>.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) shares are diving nearly 25% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318125471&amp;type=PDF&amp;symbol=SBFM&amp;cdn=6b463b17b16da81d992d83ea725b2a29&amp;companyName=Sunshine+Biopharma+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-03-01">on a delisting notice</a>.</li>



<li>Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) stock is tumbling more than 22% on a <a href="https://finance.yahoo.com/news/adial-pharmaceuticals-announces-exercise-warrants-000000236.html">major warrant exercise</a>.</li>



<li>Minim (NASDAQ:<a href="https://investorplace.com/stock-quotes/minm-stock-quote/">MINM</a>) shares are taking an almost 15% beating <a href="https://investorplace.com/2024/03/why-is-minim-minm-stock-up-43-today/">after a recent rally</a>.</li>



<li>Caledonia Mining (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cmcl-stock-quote/">CMCL</a>) stock is decreasing over 14% following its <a href="https://www.nasdaq.com/press-release/caledonia-mining-corporation-plc-trading-update-for-the-year-ended-december-31-2023">yearly investor update</a>.</li>



<li>Caravelle (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) shares are dropping close to 14% on Monday.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is sliding more than 13% on a <a href="https://www.nasdaq.com/press-release/bone-biologics-reports-progress-with-nb1-clinical-program-2024-03-01">clinical program update</a>.</li>



<li>Royalty Management (NASDAQ:<a href="https://investorplace.com/stock-quotes/rmco-stock-quote/">RMCO</a>) shares are slipping over 13% todya.</li>



<li>Envoy Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/coch-stock-quote/">COCH</a>) stock is dipping nearly 13% on Monday morning.</li>



<li>Sohu.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/sohu-stock-quote/">SOHU</a>) shares close out our pre-market stock movers down more than 12% on <a href="https://www.zacks.com/stock/news/2235099/sohucom-sohu-reports-q4-loss-lags-revenue-estimates">disappointing Q4 earnings</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-march-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!



Moving stocks this morning are a public offering, a BTC rally, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is rocketing more than 74% alongside a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318221904&amp;type=PDF&amp;symbol=LGVN&amp;cdn=137fa88e5b8c6d3013c7bd17dcc3bc85&amp;companyName=Longeveron+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-04-05">proposed public offering</a>.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are soaring over 50% after <a href="https://www.nasdaq.com/press-release/u-power-to-launch-commercial-operation-for-its-ev-battery-swapping-system-2024-04-08">announcing a commercial launch</a> for its electric vehicle (EV) battery swapping system.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is surging more than 38% alongside heavy pre-market trading.</li>



<li>Antelope (NASDAQ:<a href="https://investorplace.com/stock-quotes/aehl-stock-quote/">AEHL</a>) shares are gaining over 36% after revealing <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318222065&amp;type=PDF&amp;symbol=AEHL&amp;cdn=9905615a367a4dfc4268331afcaaa97c&amp;companyName=Antelope+Enterprise+Holdings+Limited&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-05">Weilai Zhang&rsquo;s stake in the company</a>.</li>



<li>BYND Cannasoft Enterprise (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcan-stock-quote/">BCAN</a>) stock is rising more than 28% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318222082&amp;type=PDF&amp;symbol=BCAN&amp;cdn=ea2383b9ea0254bc5206898cb5d308d3&amp;companyName=BYND+Cannasoft+Enterprises+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-05">an investment update</a>.</li>



<li>SU Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/sugp-stock-quote/">SUGP</a>) shares are increasing over 26% without any clear news this morning.</li>



<li>Earlyworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/elws-stock-quote/">ELWS</a>) stock is climbing more than 16% after announcing details for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318221064&amp;type=PDF&amp;symbol=ELWS&amp;cdn=0785738800bbd552a569313a77017370&amp;companyName=Earlyworks+Co.+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-05">general shareholder meeting</a>.</li>



<li>Valkyrie Bitcoin Futures Leveraged Strategy ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/btfx-stock-quote/">BTFX</a>) shares are heading over 14% higher after Bitcoin (<a href="https://investorplace.com/cryptocurrency/btc-usd/">BTC-USD</a>) <a href="https://www.coindesk.com/markets/2024/04/08/bitcoin-tops-71k-ordinals-bets-rise-ahead-of-halving/">surpassed $71,000 per token</a>.</li>



<li>Argo Blockchain (NASDAQ:<a href="https://investorplace.com/stock-quotes/arbk-stock-quote/">ARBK</a>) stock is jumping more than 14% on the BTC rally.</li>



<li>ProShares Trust ProShares Ultra Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITU#NYSE">BITU</a>) shares are up over 13% with the Bitcoin surge.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Perion Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/peri-stock-quote/">PERI</a>) stock is plummeting more than 38% after releasing <a href="https://finance.yahoo.com/news/perion-network-announces-preliminary-q1-100000888.html">preliminary Q1 results</a>.</li>



<li>MediaCo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdia-stock-quote/">MDIA</a>) shares are diving over 30% after a massive rally on Friday.</li>



<li>22nd Century (NASDAQ:<a href="https://investorplace.com/stock-quotes/xxii-stock-quote/">XXII</a>) stock is tumbling more than 25% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318220177&amp;type=PDF&amp;symbol=XXII&amp;cdn=cbfd27e6db838d3d11993e9c39be7897&amp;companyName=22nd+Century+Group+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-05">alongside a delisting notice</a>.</li>



<li>Eupraxia Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPRX#NASDAQ">EPRX</a>) shares are taking an over 19% beating following its <a href="https://www.nasdaq.com/press-release/eupraxia-pharmaceuticals-begins-trading-on-nasdaq-today-2024-04-05">Nasdaq debut last week</a>.</li>



<li>Caravelle (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) stock is dropping more than 17% on Monday morning.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) shares are sliding over 17% this morning.</li>



<li>Globavend (NASDAQ:<a href="https://investorplace.com/stock-quotes/gvh-stock-quote/">GVH</a>) stock is decreasing close to 17% today.</li>



<li>Zooz Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZOOZ#NASDAQ">ZOOZ</a>) shares are falling more than 15% without any clear news to report.</li>



<li>Agenus (NASDAQ:<a href="https://investorplace.com/stock-quotes/agen-stock-quote/">AGEN</a>) stock is dipping nearly 14% ahead of a <a href="https://www.nasdaq.com/press-release/agenus-announces-reverse-stock-split-of-common-stock-2024-04-05">reverse stock split</a>.</li>



<li>ProShares Trust ProShares UltraShort Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBIT#NYSE">SBIT</a>) shares close out our pre-market stock movers down over 13% with BTC&rsquo;s latest movement.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Lichen China, VirTra, Intelligent Group among industrial movers

Caravelle International (CACO) has released an update. Shareholders of Caravelle International Group have voted against a proposed reverse stock sp...

Caravelle International Shareholders Reject Stock Split

Caravelle International regains compliance with the minimum bid requirement

Caravelle International (CACO) has released an update. Caravelle International Group has regained compliance with Nasdaq's Minimum Bid Requirement ...

Caravelle International Regains Nasdaq Compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
June may not be the first month you consider when you plan to invest, but this isn&rsquo;t a month that should be overlooked. June is an ideal time to look for A-rated <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to diversify your portfolio and lead to some potentially lucrative returns.



Penny stocks are shares of companies with stock valued under $5. It&rsquo;s appealing to investors since they can acquire a significant stake in a company with a small investment.



However, not all penny stocks are created equal, and the risks associated with them can be substantial. This is where A-rated penny stocks come into play.



A-rated penny stocks get their rankings from the Portfolio Grader, which assigns stocks a letter grade based on earnings performance, growth, analyst sentiment and buying momentum. By keeping your eye on A-rated penny stocks, you&rsquo;re assured of getting the best of these low-priced stocks and setting yourself up for a better overall return.



And with June being a popular month for companies to file earnings reports, investors are armed with new information about these companies&rsquo; performance and outlook.



There are seven A-rated penny stocks on today&rsquo;s list, and any of them would be a solid addition to a portfolio while mitigating the risks that are commonly associated with smaller companies.



<h2>Lexaria Bioscience (LEXX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div>Biotech companies can be challenging investments. Bringing a drug to market is no small feat, as it requires millions of dollars in research and development and multiple successful clinical trials before you can even consider seeking regulatory approval and achieve commercialization.



But Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) is an exception to the rule. The company is the creator of DehydraTECH, which is a drug delivery technology that improves the way active drugs enter the bloodstream.



DehydraTECH increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled tablets, capsules and oral suspensions because it can mask the taste of medications.



Biotechs can incorporate the DehydraTECH platform into any of their oral medications to make them more effective and tolerable for patients.



Any drug delivery system that makes medications more effective and more tolerable to patients is going to be popular in the biotech field.



The DehydraTECH platform increases the absorption of the drug into a patient and helps the medication take effect faster. It also reduces the need for sugar-filled products because it can mask the taste of medications.



At the end of the <a href="https://ir.lexariabioscience.com/financial-information/financial-results">second quarter</a>, Lexaria was in a strong cash position, with $4.7 million on hand. Revenue in the quarter was only $145,000, but that is better than the $20,000 the company received in the second fiscal quarter of 2023. The company reported a loss of $668,000, but its losses are significantly dropping as the company edges toward profitability.



LEXX stock is up 130% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>JanOne (JAN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>JanOne (NASDAQ:<a href="https://investorplace.com/stock-quotes/jan-stock-quote/">JAN</a>) is yet another bioscience company. It is developing nonaddictive treatments for conditions that cause severe pain. Its work is dedicated to helping people manage their pain without getting hooked on a treatment and developing a dependency for a drug, such as opioids.



Its most promising drug in the pipeline is a treatment for peripheral artery disease. The drug candidate has successfully completed Phase 2A trials and is awaiting Phase 2B testing to treat the disease and the pain associated with peripheral artery disease.



In addition, JanOne has a wholly owned subsidiary called <a href="https://ir.janone.com/news-events/press-releases/detail/71/janones-subsidiary-alt5-reports-91-year-over-year">ALT5 Sigma</a>, which is a fintech company that provides next-generation blockchain powered technologies. The company processed $289 million in cryptocurrency transactions in April and May combined, which was a 91% increase from a year ago.



JanOne offers an interesting way to invest in biotech and also play the cryptocurrency space. The stock is up 333% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Ocugen (OCGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/ocgn1600-300x169.png" alt="Person holding smartphone with logo of US biopharmaceutical company Ocugen Inc. (OCGN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>As a small biotech company headquartered in Pennsylvania, Ocugen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocgn-stock-quote/">OCGN</a>) is making its mark by developing and commercializing gene and cell therapies.



The company is also getting a nice boost on June 28 when it joins the Russell 3000 index, which measures the performance of the largest 3,000 U.S. companies. Its inclusion means that Ocugen stock will be included in exchange traded funds and products that track the Russell 3000.



Ocugen is working on a breakthrough modifier gene therapy product that might treat multiple retinal diseases with a single product. It also has several products in various phases of testing to treat eye diseases.



Ocugen showed $13.2 million in operating expenses for the first quarter and had $26.4 million of cash on hand. It posted a loss of 5 cents per share versus a loss of 8 cents per share a year ago.



Losses for small biotech companies are to be expected as it takes time and money to bring new therapies to market. But OCGN stock is one of the better penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> you can buy, as the stock is up 124% so far this year. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Kuke Music (KUKE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/02/music_1600-300x169.jpg" alt="A photo of someone writing out music on staff paper with guitars in the background."><div>Source: Kemedo/ShutterStock.com</div></div>Kuke Music (NYSE:<a href="https://investorplace.com/stock-quotes/kuke-stock-quote/">KUKE</a>) is a digital music company in China. The company is a leading provider of classical music licensing, subscriptions and smart education services in China.



The company leverages its diverse content offerings and experience in music education to provide smart music education products, including Kuke smart pianos and Kuke smart teaching systems.



The company is also the organizer of the Beijing Music Festival and is working to get into the AI music field through a <a href="https://finance.yahoo.com/news/kuke-jidou-join-forces-ai-122000084.html">partnership</a> with Shanghai Jidou Science and Technology, which will see Kuke lauch an AI music application through a digital automotive software platform that Jidou develops for more than a dozen automotive companies.



<a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=318325464&amp;type=HTML&amp;cdn=2794ad5ad1fb979a4aae2110f8badbd2&amp;formType=20-F&amp;dateFiled=2024-05-15&amp;cik=0001809158&amp;symbol=0001809158&amp;companyName=">Kuke and its subsidiaries</a> reported revenue in 2023 of 106.9 million Chinese yuan ($14.7 million) and a loss of 65.8 million Chinese yuan. But the AI music partnership provides a path for Kuke to turn those losses into profits.



KUKE stock is up 101% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Jin Medical (ZJYL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/penny-stocks-single-300x169.jpg" alt="A close up photo of a penny. Penny Stocks to Buy"><div>Source: Shutterstock</div></div>Jin Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/zjyl-stock-quote/">ZJYL</a>) is another Chinese penny stock. The company makes and sells wheelchairs and other products for the elderly and those with disabilities.



The company operates two manufacturing plants with approximately 228,257 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. And it has relationships with more than 40 distributors in China and distributors in 20 other regions.



The majority of the company&rsquo;s wheelchair products, which includes 30 models, are sold in China and Japan.



As a Chinese company, Jin doesn&rsquo;t report its financials as often as those based in the U.S. But its <a href="https://ir.zhjmedical.com/se%D1%81filings">most current financial report</a> for the 2023 fiscal year (ending Sept. 30, 2023), included revenue of $19.8 million, up 3% from a year ago. 



Profits of $6.7 million were up 9.5% from the 2022 fiscal year, and total net income of $2.87 million was a 6.3% improvement from the previous year.



ZJYL stock, which had its initial public offering only a year ago, is having a rough 2024. The company performed a <a href="https://investorplace.com/2024/02/why-is-jin-medical-international-zjyl-stock-moving-today/">20-for-1 stock split,</a> which brought the stock price down from $217 to roughly $13.50. However, the stock has been slipping ever since, and is down in penny stock territory.



However, I&rsquo;m expecting a rebound based on the company&rsquo;s financials, and the stock currently maintains its &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Caravelle International (CACO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/tech-stocks-1600-300x169.png" alt="A hexagonal grid with different tech-related icons; Tech stocks illustration. Best Tech stocks. tech stocks trading at bargain prices"><div>Source: whiteMocca / Shutterstock</div></div>Caravelle International (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) is a global ocean technology company with headquarters in Singapore. The company has routes to 50 companies and serves more than 100 ports.



Caravelle&rsquo;s innovation lies in its work with shipping and lumber industries. The company invented a patent pending process called CO-Tech, which uses the heat from its ships&rsquo; exhaust to dry wood during transportation.



Caravelle says the process is an improvement from the lumber industry&rsquo;s practice of building and maintaining wood drying facilities and the energy required to heat the wood in those facilities.



Contrast this to the traditional wood desiccation process where lumber companies must build and maintain expensive wood drying facilities, spend money on energy to heat the wood, and emit massive amounts CO2.



The company already has a <a href="http://www.caravelleglobal.com/news-detail.html?newId=1783843089586188289">memorandum of understanding</a> with the government of Gabon to provide dried timber. If it can expand the business model to other governments, Caravelle may have a groundbreaking business on its hands.



CACO stock is up 63% this year, but is still priced at less than $1 per share. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Eco Wave Power (WAVE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1932365063-300x169.png" alt="Environmental protection, renewable, sustainable energy sources. Plant growing in the bulb concept. renewable energy stocks to buy"><div>Source: Proxima Studio / Shutterstock.com</div></div>Eco Wave Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) is a clean energy company that develops electricity from the power of ocean waves. 



If you&rsquo;ve ever been caught in a rough surf you know that even those waves can pack a punch, so imagine the power that an ocean wave can provide should we be able to harness that power and turn it into a clean source of electricity.



The company&rsquo;s floaters can be attached to human-made structures to simplify installation and maintenance. The floaters draw energy from incoming waves by converting the rising and falling motion into a clean energy generation process.



The company currently works with customers in Israel, Portugal, Los Angeles and Gibraltar, a British territory. 



While there was no revenue in the first quarter and the company sustained an operating loss of $659,000, management has high hopes that the company&rsquo;s clean energy solution will be a powerful argument for coastal cities.



WAVE stock is up 79% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-a-rated-penny-stocks-to-beat-june-gloom/">7 A-Rated Penny Stocks to Beat June Gloom</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Penny Stocks to Beat June Gloom

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Wednesday with our breakdown of all the biggest news affecting shares this morning.



Moving stocks this morning are merger agreements, eaernings reports, late filings notices and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Vivopower (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) stock is rocketing more than 75% as its Tembo subsidiary <a href="https://www.nasdaq.com/press-release/vivopowers-tembo-confirms-heads-agreement-exclusivity-extension-us-838m-merger-ccts">prepares for a merger</a>.</li>



<li>Zoomcar (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) shares are soaring over 33% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318428597&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=815824f42d62c01bbe441848d3eae09a&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-01">departure of its CEO</a> and a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318432468&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=dc00ab75a334038308b226d996648882&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=NT+10-K&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-K+405%2C+10-K%2C+10-KSB+405%2C+10-KSB%2C+10-KT%2C+or+10-KT405&amp;dateFiled=2024-07-02">late filing notice</a>.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) stock is surging more than 27% alongside heavy pre-market trading.</li>



<li>Caravelle (NASDAQ:<a href="https://investorplace.com/stock-quotes/caco-stock-quote/">CACO</a>) shares are gaining over 24% without any clear news this morning.</li>



<li>CureVac (NASDAQ:<a href="https://investorplace.com/stock-quotes/cvac-stock-quote/">CVAC</a>) stock is increasing more than 23% on <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-buys-full-rights-make-covid-influenza-vaccines-curevac-2024-07-03/">news of a vaccine sale</a>.</li>



<li>DouYu (NASDAQ:<a href="https://investorplace.com/stock-quotes/doyu-stock-quote/">DOYU</a>) shares are rising over 22% after announcing a <a href="https://www.nasdaq.com/press-release/douyu-international-holdings-limited-announces-special-cash-dividend-2024-07-03">special cash dividend</a>.</li>



<li>MSP Recovery (NASDAQ:<a href="https://investorplace.com/stock-quotes/lifw-stock-quote/">LIFW</a>) stock is heading more than 20% higher despite a lack of news this morning.</li>



<li>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) shares are climbing over 19% without any obvious news to report.</li>



<li>Scilex (NASDAQ:<a href="https://investorplace.com/stock-quotes/sclx-stock-quote/">SCLX</a>) stock is jumping more than 18% as subsidiary Semnur Pharmaceuticals <a href="https://www.globenewswire.com/news-release/2024/07/02/2907841/0/en/Semnur-Pharmaceuticals-Inc-a-Wholly-Owned-Subsidiary-of-Scilex-Holding-Company-and-Denali-Capital-Acquisition-Corp-Nasdaq-DECA-Enter-into-a-Letter-of-Intent-for-a-Proposed-Business.html">enters a merger agreement</a>.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are up close to 18% after <a href="https://www.nasdaq.com/press-release/u-power-expands-global-footprint-strategic-move-thai-market-2024-07-03">announcing an expansion into Thailand</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shapeways (NASDAQ:<a href="https://investorplace.com/stock-quotes/shpw-stock-quote/">SHPW</a>) stock is plummeting over 39% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318434959&amp;type=PDF&amp;symbol=SHPW&amp;cdn=ad248035b57b9d6b5efbd20955a6955d&amp;companyName=Shapeways+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-03">filing for Chapter 7 bankruptcy</a>.</li>



<li>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) shares are diving more than 27% with the release of its <a href="https://www.nasdaq.com/press-release/first-foundation-inc-announces-second-quarter-2024-earnings-conference-call-details">Q2 earnings report</a>.</li>



<li>Upexi (NASDAQ:<a href="https://investorplace.com/stock-quotes/upxi-stock-quote/">UPXI</a>) stock is taking an over 13% beating <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318432555&amp;type=PDF&amp;symbol=UPXI&amp;cdn=9b1bbc06760a8be879bdd983cb8a3296&amp;companyName=Upexi+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-07-02">with a late filing</a>.</li>



<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) shares are tumbling more than 13% after <a href="https://www.nasdaq.com/press-release/eshallgo-inc-announces-pricing-initial-public-offering-2024-07-01">pricing a public offering</a>.</li>



<li>Universe Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/upc-stock-quote/">UPC</a>) stock is sliding over 12% this morning.</li>



<li>Noah (NYSE:<a href="https://investorplace.com/stock-quotes/noah-stock-quote/">NOAH</a>) shares are falling more than 10% without any apparent news today.</li>



<li>Sunrise New Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) stock is dropping over 9% this morning.</li>



<li>Ocean Power Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/optt-stock-quote/">OPTT</a>) shares are decreasing more than 9% <a href="https://investorplace.com/2024/07/why-is-ocean-power-optt-stock-up-80-today/">after a rally yesterday</a>.</li>



<li>Forge Global (NYSE:<a href="https://investorplace.com/stock-quotes/frge-stock-quote/">FRGE</a>) stock is slipping nearly 9% on Wednesday.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares close out our pre-market stock movers down over 8% after a Tuesday rally.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-3rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Caravelle International (CACO) has released an update. Caravelle International Group has undergone a major restructuring with a series of high-prof...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Caravelle Intl Gr

Caravelle Intl Gr (CACO) Forecast

Caravelle Intl Gr (NASDAQ:CACO) Stock, Quote.Headers.trade-ideas